Pharmaceutical compound
Identifiers | |
---|---|
IUPAC name
| |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL |
|
Chemical and physical data | |
Formula | C21H24N2O4S |
Molar mass | 400.49 gยทmol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Anaprazole is a pharmaceutical drug used for the treatment of duodenal ulcers. It is classified as a proton pump inhibitor (PPI). It was approved for use in China in 2023. It is formulated as its sodium salt, anaprazole sodium, in enteric-coated tablets.
References
- Wang F, Niu X, Liu F, Ma X, Cheng F, Xu H, et al. (July 2024). "Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects". Clinical Pharmacology in Drug Development. 13 (7): 782โ789. doi:10.1002/cpdd.1405. PMID 38629191.
- ^ "Anaprazole Sodium Enteric-coated Tablets Approved for Marketing by China NMPA". Chinese National Medical Products Administration. 2023-06-25.
Drugs for peptic ulcer and GERD/GORD (A02B) | |
---|---|
H2 antagonists ("-tidine") | |
Prostaglandins (E)/ analogues ("-prost-") | |
Proton-pump inhibitors ("-prazole") | |
Potassium-competitive acid blockers ("-prazan") | |
Others | |
Combinations | |
|
This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |